REMARKS

Amendments

Claims 1-9 and 12-17 have been amended to place the claims in accordance with U.S. patent practice. Additionally, exemplary embodiments have been deleted from claims 1-8 and 14-16 and presented as new claims 18-26, as shown in the following table:

New Claim	Supported by exemplary embodiments deleted from amended claim(s):	Support for new claim in specification
18	1-4	pages 1-10
19	5	p. 16, lines 6-14
20	6	p. 17, l. 17 - p. 18, l. 4
21-22	7	p. 18, lines 8-21
23	8	p. 19, l. 11-p. 20, l. 6
24	14	p. 24, lines 12-16
25	15	p. 24, lines 12-16
26	16	p. 24, lines 12-16

Additionally, new claims 19, 20, 22, and 23 recite the complete names of the compounds or chemical groups whose acronyms were used in original claims 5-8. A list of acronyms used in the application is found on pages 47-48 of the disclosure. Claims 10 and 11 have been canceled.

No new matter is introduced by any of the amendments herein.

Claims 1-9 and 12-17 -Version With Markings to Show Chang s Made:

1. A compound of general Formula I



(I)

or a pharmaceutically acceptable salt or solvate thereof, or a solvate of such a salt, wherein:

R_1 is selected from the group consisting of: [represents,]

C_1-C_6 alkyl, substituted with one or more basic groups [such as amino, amidino and/or guanidino];

cycloalkyl, substituted with one or more basic groups [such as amino, amidino and/or guanidino];

heterocyclyl, comprising [containing] at least one nitrogen atom;

heterocyclyl, comprising [containing] at least one hetero atom selected from S or O, and substituted with one or more basic groups [such as amino, amidino and/or guanidino]; and

[or] aryl, substituted with one or more basic groups; [such as amino, amidino and/or guanidino,]

R_2 is selected from the group consisting of [represents] H, acyl, acylamino, alkyl, alkylcarbamoyl, alkylthio, alkoxy, aroyl, aroylamino, aryloxy, arylthio, amidino, amino, aryl, carbamoyl, carboxy, cyano, cycloalkyl, formyl, guanidino, halogen, heterocyclyl, hydroxy, oxo, nitro, thiol, Z_2N-CO-O-, ZO-CO-NZ-, and [or] Z_2N-CO-NZ-; [group,]

R_3 is selected from the group consisting of [represents] $COOR_5$, $SO(OR_5)$, SO_3R_5, $P{=}O(OR_5)_2$, $B(OR_5)_2$, $P{=}OR_5(OR_5)$, [or] tetrazole, and a [or any] carboxylic acid isostere; [,]

R_4 is [represents] a  -group, [or] a  -group, or a  -group; [,]

[roup]

R_5 is [represents] H, C_1-C_6 alkyl, or aryl; [,]

R_6 is [represents] C_1-C_6 alkyl, aryl, cycloalkyl, heterocyclyl, or an optionally N-substituted

H_2N-C(Z)-CONH-C(Z)- or H_2N-C(Z)- group; [,]

R_7 is [represents] H or C_1-C_6 alkyl; [,]

X is selected from the group consisting of [represents] O, S, SO, SO_2, $C(Z)_2$, N(Z), NR_7SO_2, SO_2NR_7, NR_7CO, and [or] $CONR_7$; [,]

Y is selected from the group consisting of [represents] O, N(Z), S, $C(Z)_2$, and [or] a single bond; and [,]

Z is [represents] independently selected from the group consisting of H, C_1-C_6 alkyl, aryl, cycloalkyl, and [or] heterocyclyl,

with the proviso that when X is [represents] O, S, SO, SO_2, N(Z), NR_7SO_2, SO_2NR_7, or NR_7CO, then Y is [represents] $C(Z)_2$ or a single bond.

2. The compound according to claim 1, or a pharmaceutically acceptable salt or solvate thereof, or a solvate of such a salt,

wherein:

R_1 is selected from the group consisting of: [represents,]

cycloalkyl, substituted with one or more basic groups [such as amino, amidino and/or guanidino];

heterocyclyl, comprising [containing] at least one nitrogen atom; and

heterocyclyl, comprising [containing] at least one hetero atom selected from S or O, and substituted with one or more basic groups [such as amino, amidino and/or guanidino];

R_2 is selected from the group consisting of [represents] H, C_1-C_3 alkyl, amino, halogen, and hydroxy; [,]

R_3 is [represents] $COOR_5$; [,]

R_4 is [represents] a  -group; [,]

R_5 is [represents] H, C_1-C_6 alkyl, or aryl; [,]

R_6 is [represents] C_1-C_6 alkyl, aryl, cycloalkyl, heterocyclyl, or an optionally N-substituted

H_2N-C(Z)-CONH-C(Z)- or H_2N-C(Z)- group; [,]

X is [represents] $C(Z)_2$; [,]

Y is [represents] O or $C(Z)_2$; and [,]

Z is [represents] independently H or C_1-C_6 alkyl.

3. The compound according to claim 1, or a pharmaceutically acceptable salt or solvate thereof, or a solvate of such a salt,

wherein;

R_1 is selected from the group consisting of: [represents,]

cycloalkyl, substituted with one or more basic groups [such as amino, amidino and/or guanidino];

heterocyclyl, comprising [containing] at least one nitrogen atom; and

heterocyclyl, comprising [containing] at least one hetero atom selected from S or O, and substituted with one or more basic groups [such as amino, amidino and/or guanidino];

R_2 is selected from the group consisting of [represents] H, C_1-C_3 alkyl, amino, halogen, and [or] hydroxy; [,]

R_3 is [represents] $COOR_5$; [,]

R_4 is [represents] a  -group,

R_5 is [represents] H, C_1-C_6 alkyl, or aryl; [,]

R_7 is [represents] H or C_1-C_6 alkyl; [,]

X is [represents] $C(Z)_2$; [,]

Y is [represents] $C(Z)_2$ [,] or a single bond; and [,]

Z is [represents] independently H or C_1-C_6 alkyl.

4. The compound according to claim 1, or a pharmaceutically acceptable salt or solvate thereof, or a solvate of such a salt,
wherein

R_1 is selected from the group consisting of: [represents,]

cycloalkyl, substituted with one or more basic groups [such as amino, amidino and/or guanidino];

heterocyclyl, comprising [containing] at least one nitrogen atom; and

heterocyclyl, comprising [containing] at least one hetero atom selected from S or O, and substituted with one or more basic groups [such as amino, amidino and/or guanidino];

R_2 is selected from the group consisting of [represents] H, C_1-C_3 alkyl, amino, halogen, and [or] hydroxy; [,]

R_3 is [represents] $COOR_5$; [,]

R_4 is [represents] a  R_5-group; [,]

R_5 is [represents] H, C_1-C_6 alkyl, or aryl; [,]

X is [represents] $C(Z)_2$; [,]

Y is [represents] $C(Z)_2$ [,] or a single bond; and [,]

Z is [represents] independently H or C_1-C_6 alkyl.

5. A process for the preparation of a compound according to any one of claims 1-4, wherein R_1, R_5, R_6, and Z are as defined in claim 1, [and] R_2 is H, R_3 is $COOR_5$,

R_4 is [represents] a  -group,

X is $C(Z)_2$, and Y is $C(Z)_2$,

comprising the step of:

reacting a compound of Formula VI,



(VI)

wherein R_1 and Z is as defined in claim 1, [and] X is $C(Z)_2$, and Y is $C(Z)_2$, with a compound of Formula IX,

$$R_6PO_2H_2 \qquad (IX)$$

wherein R_6 is as defined in claim 1, in the presence of a [suitable] reagent, [such as BSA or HMDS,] under standard conditions.

6. A process for the preparation of a compound according to any one of claims 1-4, wherein R_1, R_2, R_5, R_6, and Z are as defined in claim 1, R_3 is $COOR_5$, X is $C(Z)_2$, Y is O, and

R_4 is [represents] a  -group,

comprising the step of:

reacting a compound of Formula XII,



(XII)

wherein R_1 and R_2 are as defined in claim 1 and X is $C(Z)_2$, with a compound of Formula XIII,

$$R_6PO_3H_2 \qquad (XIII)$$

wherein R_6 is as defined in claim 1, in the presence of a [suitable] coupling reagent[s such a DCC/DMAP, PyBop/DIPEA or $SOCl_2$,] under standard conditions.

7. A process for the preparation of a compound according to any one of claims 1-4, wherein R_1 and R_2 are as defined in claim 1, [and] X and Y are independently [is] $C(Z)_2$ or a single bond, and R_3 and R_4 are $COOR_5$, comprising the step of:

reacting a compound of Formula XIV,



(XIV)

wherein R_2 and R_5 are as defined in claim 1, and Y is $C(Z)_2$ or a single bond, with a compound of the general Formula III,

$$R1{-}X{-}L \qquad (III)$$

wherein R_1 is as defined in claim 1, X is $C(Z)_2$, and L is a [suitable] leaving group, [such as Cl, Br, I or tosyl,] in the presence of a [suitable] base, [such as LDA or NaH,] under standard conditions.

8. A process for the preparation of a compound according to any one of claims 1-4, wherein R_1, R_2, R_5, R_7, X, Y and Z are as defined in claim 1, R_3 is $COOR_5$ and

R_4 is [represents] a  -group,

comprising the step of:
reacting a compound of Formula XV,



(XV)

with a compound of Formula XVI,

$$HR_7NOH \qquad (XVI)$$

wherein R_7 is as defined in claim 1, in the presence of a [suitable] reagent[s, such as DCC/DMAP,] under standard conditions.

9. A pharmaceutical formulation comprising [containing] a compound according to any one of claims 1-4 as active ingredient in combination with a pharmaceutically acceptable adjuvant, diluent, or carrier.

12. A method for the treatment or prophylaxis of conditions associated with inhibition of carboxypeptidase U, comprising administering to a patient [mammal, including man,] in need of such treatment an effective amount of a compound according to [as defined in] any one of claims 1-4.

13. A pharmaceutical formulation for [use in] the treatment or prophylaxis of conditions associated with inhibition of carboxypeptidase U, comprising a compound according to [as defined in] any one of claims 1-4 in combination with a pharmaceutically acceptable adjuvant, diluent, or carrier.

14. A pharmaceutical formulation, comprising:

(i) a compound of Formula I as defined in claim 1 or a pharmaceutically acceptable salt or solvate thereof, or a solvate of such a salt; [,] and

(ii) one or more antithrombotic agents with a different mechanism of action from that of component (i), [such as an antiplatelet agent, thromboxane receptor inhibitor, synthetase inhibitor, fibrinogen receptor antagonist, prostacyclin mimetic, phosphodiesterase inhibitor or ADP-receptor (P_2T) antagonist,]

in admixture with a pharmaceutically acceptable adjuvant, diluent, or carrier.

15. A kit of parts comprising:

(i) a pharmaceutical formulation comprising [containing] a compound of Formula I as defined in claim 1, or a pharmaceutically acceptable salt or solvate thereof, or a solvate of such a salt, in admixture with a pharmaceutically acceptable adjuvant, diluent or carrier; and

(ii) a pharmaceutical formulation comprising [containing] one or more antithrombotic agents with a different mechanism of action from that of component (i), [such as an antiplatelet agent, thromboxane receptor inhibitor, synthetase inhibitor, fibrinogen receptor antagonist, prostacyclin mimetic, phosphodiesterase inhibitor or ADP-receptor (P_2T) antagonist,] in admixture with a pharmaceutically acceptable adjuvant, diluent or carrier;

wherein [which] compound (i) and agent (ii) are each formulated [provided in a form that is suitable] for administration in conjunction with the other.

16. A method for treatment of a patient suffering from, or susceptible to, a condition in which inhibition of carboxypeptidase U and a different antithrombotic mechanism are required or desired, which method comprises administering to the patient a therapeutically effective total amount of:

(i) a compound of Formula I, or a pharmaceutically acceptable salt or solvate thereof, or a solvate of such a salt, in admixture with a pharmaceutically acceptable adjuvant, diluent or carrier; and [in conjunction with]

(ii) one or more antithrombotic agents with a different mechanism of action from that of component (i), [such as an antiplatelet agent, thromboxane receptor inhibitor, synthetase inhibitor, fibrinogen receptor antagonist, prostacyclin mimetic, phosphodiesterase inhibitor or ADP-receptor (P_2T) antagonist,] in admixture with a pharmaceutically acceptable adjuvant, diluent, or carrier.

17. A method for treatment of a patient suffering from, or susceptible to, a condition in which inhibition of carboxypeptidase U and a different antithrombotic mechanism are required or desired, which method comprises administering to the patient a formulation from the kit of [as defined in] claim 15.

CONCLUSION

Upon entry of this Preliminary Amendment, claims 1-9 and 12-26 are pending. Applicants respectfully submit that claims 1-9 and 12-26 are directed to patentable subject matter. Accordingly, Applicant requests allowance of the claims.

Authorization is hereby given to charge any fee in connection with this communication to Deposit Account No. 23-1703.

Dated: NOV 5, 2001

Respectfully submitted,

Andrew Fessak

Andrew Fessak
Reg. No. 48,528

Customer No. 07470
Direct Line: (212) 819-8437